title: The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.
abstract: Novel agents including immunomodulatory drugs and proteasome inhibitors incorporated into induction regimens and subsequently followed by autologous stem cell transplantation in cases of multiple myeloma have resulted in enhancement of response rate and its depth. Maintaining or even improving the response is an important treatment goal. Most clinical trials have revealed increased progression-free survival after consolidation and maintenance therapy. Some of them have also shown prolongation of overall survival. However, continuous therapy may be associated with significant side effects and costs, and therefore remains controversial. Treatment decisions should be individualized and based upon projected benefits and risks.
authors.affiliation: Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
authors.forename: Monika
authors.initials: M
authors.lastname: Joks
authors.forename: Artur
authors.initials: A
authors.lastname: Jurczyszyn
authors.forename: Maciej
authors.initials: M
authors.lastname: Machaczka
authors.forename: Aleksander B
authors.initials: AB
authors.lastname: Skotnicki
authors.forename: Mieczysław
authors.initials: M
authors.lastname: Komarnicki
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D060830:Consolidation Chemotherapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D060046:Maintenance Chemotherapy; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000209:etiology; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib
keywords: autologous stem cell transplantation; bortezomib; consolidation; lenalidomide; maintenance; multiple myeloma